Difference between revisions of "Rebimastat (BMS-275291)"
Jump to navigation
Jump to search
m (Jwarner moved page BMS-275291 to Rebimastat (BMS-275291)) |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bms-275291 NCI Drug Dictionary]: A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called matrix metalloproteinase inhibitors (MMPIs). | From the [https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bms-275291 NCI Drug Dictionary]: A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called matrix metalloproteinase inhibitors (MMPIs). | ||
| + | |||
| + | ==Also known as== | ||
| + | *''Code names:''' BMS-275291, D2163 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 19:57, 20 June 2023
Mechanism of action
From the NCI Drug Dictionary: A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called matrix metalloproteinase inhibitors (MMPIs).
Also known as
- Code names:' BMS-275291, D2163